248 results on '"Yendamuri S"'
Search Results
152. Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma.
- Author
-
Platz TA, Nurkin SJ, Fong MK, Groman A, Flaherty L, Malhotra U, Levea CM, Yendamuri S, Warren GW, Nava HR, and May KS
- Abstract
Background: Esophageal/gastroesophageal junction (GEJ) adenocarcinoma is increasingly treated with trimodality therapy. We present our experience using carboplatin/paclitaxel and radiotherapy followed by surgery., Methods: Consecutive patients with distal esophageal/GEJ adenocarcinoma (≥T2 or N+) treated from July 2010 to October 2011 were identified. Treatment included neoadjuvant carboplatin/paclitaxel with concurrent radiotherapy (CRT) to 50.4 Gy using an IMRT technique and then Ivor Lewis esophagogastrectomy (ILE). PET/CT was performed prior to and after CRT. Patient/treatment characteristics and tumor response were analyzed., Results: Over this timeframe, 16 patients completed trimodality therapy. All were male, median age of 60 years (45-72 years). All tumors were grade 2-3 with mean tumor length of 4.4 cm (1-9 cm). A median of 6 cycles (5-9 cycles) neoadjuvant carboplatin/paclitaxel were administered. Average time from diagnosis to CRT completion was 76 days (44-141 days) and 60 days (35-92 days) from CRT end to surgery. Neoadjuvant CRT was well tolerated with mean weight loss of 3.9 kg. All pts had R0 resections. No anastomotic leaks or perioperative mortality occurred. Mean hospital stay was 13 days (8-28 days). Pathologic complete response (pCR) was seen in 38% of patients, microscopic residual disease (isolated tumor cells or <2 mm) in 31%, and macroscopic residual disease remained in 31%. Mean SUV reduction was 41% (0-100%). Of 11 patients with ≥35% SUV decrease, 45% had pCR and 27% had microscopic residual disease. Three patients had signet ring features. Of these, 2 had no SUV reduction and all had gross residual disease, including the only patient with positive nodal disease., Conclusions: Trimodality therapy utilizing concurrent carboplatin/paclitaxel and radiotherapy to 50.4 Gy followed by surgery was well tolerated and resulted in significant pathologic complete response or minimal residual disease. Further investigation of predictive factors for response is needed to best tailor therapy in the management of esophageal/GEJ adenocarcinoma.
- Published
- 2013
- Full Text
- View/download PDF
153. Reply to the editor.
- Author
-
Yendamuri S and Demmy TL
- Subjects
- Humans, Carcinoma, Non-Small-Cell Lung diagnosis, Lung Neoplasms diagnosis, Lymph Node Excision methods, Lymph Node Excision standards, Lymph Nodes pathology, Mediastinoscopy standards, Video-Assisted Surgery standards
- Published
- 2013
- Full Text
- View/download PDF
154. [Advance in lung cancer surgery].
- Author
-
Hennon MW and Yendamuri S
- Subjects
- Humans, Lung Neoplasms pathology, Neoplasm Staging, General Surgery methods, Lung Neoplasms surgery
- Published
- 2013
- Full Text
- View/download PDF
155. Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression.
- Author
-
Nwogu CE, Yendamuri S, Tan W, Kannisto E, Bogner P, Morrison C, Cheney R, Dexter E, Picone A, Hennon M, Hutson A, Reid M, Adjei A, and Demmy TL
- Subjects
- Aged, Aged, 80 and over, Antigens, Tumor-Associated, Carbohydrate metabolism, Biomarkers, Tumor metabolism, Carcinoembryonic Antigen metabolism, Female, Fluorodeoxyglucose F18, Humans, Keratin-7 metabolism, Lymphangiogenesis, Male, Middle Aged, Multimodal Imaging, Neoplasm Staging, Positron-Emission Tomography, Radiopharmaceuticals, Receptors, Vascular Endothelial Growth Factor metabolism, Statistics, Nonparametric, Tomography, X-Ray Computed, Lung Neoplasms metabolism, Lung Neoplasms pathology, Lymph Nodes metabolism, Lymph Nodes pathology, Lymphatic Metastasis pathology, Neoplasm Micrometastasis pathology, Real-Time Polymerase Chain Reaction, Vascular Endothelial Growth Factor A metabolism
- Abstract
Objectives: Lymph node staging provides critical information in patients with non-small cell lung cancer (NSCLC). Lymphangiogenesis may be an important contributor to the pathophysiology of lymphatic metastases. We hypothesized that the presence of lymph node micrometastases positively correlates with vascular endothelial growth factors (VEGFs) A, C, and D as well as VEGF-receptor-3 (lymphangiogenic factors) expression in lymph nodes., Methods: Forty patients with NSCLC underwent preoperative positron emission tomography-computed tomography and mediastinoscopy. Real-time polymerase chain reaction (RT-PCR) assays for messenger RNA expression of epithelial markers (ie, cytokeratin 7; carcinoembryonic antigen-related cell adhesion molecule 5; and palate, lung, and nasal epithelium carcinoma-associated protein) were performed in selected fluorodeoxyglucose-avid lymph nodes. VEGF-A, VEGF-C, VEGF-D, and VEGF receptor-3 expression levels were measured in primary tumors and lymph nodes. Wilcoxon rank sum test was run for the association between the RT-PCR epithelial marker levels and VEGF expression levels in the lymph nodes., Results: RT-PCR for cytokeratin 7; carcinoembryonic antigen-related cell adhesion molecule 5; or palate, lung, and nasal epithelium carcinoma-associated protein indicated lymph node micrometastatic disease in 19 of 35 patients (54%). There was a high correlation between detection of micrometastases and VEGF-A, VEGF-C, VEGF-D, or VEGF receptor-3 expression levels in lymph nodes. Median follow-up was 12.6 months., Conclusions: RT-PCR analysis of fluorodeoxyglucose-avid lymph nodes results in up-staging a patient's cancer. Micrometastases correlate with the expression of VEGF in lymph nodes in patients with NSCLC. This may reflect the role of lymphangiogenesis in promoting metastases., (Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
156. Reply: To PMID 21704299.
- Author
-
Yendamuri S and Demmy TL
- Subjects
- Female, Humans, Male, Carcinoid Tumor surgery, Lung Neoplasms surgery, Pneumonectomy methods
- Published
- 2013
- Full Text
- View/download PDF
157. Is VAMLA/TEMLA the new standard of preresection staging of non-small cell lung cancer?
- Author
-
Yendamuri S and Demmy TL
- Subjects
- Carcinoma, Non-Small-Cell Lung secondary, Carcinoma, Non-Small-Cell Lung therapy, Humans, Lung Neoplasms pathology, Lung Neoplasms therapy, Lymph Nodes surgery, Lymphatic Metastasis, Neoadjuvant Therapy, Neoplasm Staging, Practice Guidelines as Topic standards, Predictive Value of Tests, Prognosis, Thoracic Surgical Procedures, Carcinoma, Non-Small-Cell Lung diagnosis, Lung Neoplasms diagnosis, Lymph Node Excision methods, Lymph Node Excision standards, Lymph Nodes pathology, Mediastinoscopy standards, Video-Assisted Surgery standards
- Abstract
Accurate mediastinal staging is the hallmark of a good thoracic oncology program. Mediastinal lymph node staging is important for prognostication and to guide the administration of neoadjuvant and adjuvant therapy. In addition, accurate mediastinal staging is necessary for a fair comparison of different clinical studies. The most important surgical advance in mediastinal lymph node staging in the past few years is transcervical staging, by either sternal elevation or video-assisted mediastinoscopy. The present report summarizes the existing published data evaluating such an approach., (Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
158. Thoracoscopic maneuvers for chest wall resection and reconstruction.
- Author
-
Demmy TL, Yendamuri S, Hennon MW, Dexter EU, Picone AL, and Nwogu C
- Subjects
- Humans, Osteotomy, Pneumonectomy adverse effects, Plastic Surgery Procedures adverse effects, Ribs surgery, Treatment Outcome, Video Recording, Pneumonectomy methods, Plastic Surgery Procedures methods, Thoracic Wall surgery, Thoracoscopy adverse effects
- Abstract
Objective: The aim of this report is to describe technical maneuvers used to complete minimally invasive resections of the chest wall successfully., Methods: Case videos of advanced thoracoscopic chest wall resections performed at a comprehensive cancer center were reviewed, as were published reports. These were analyzed for similarities and also categorized to summarize alternative approaches., Results: Limited chest wall resections en bloc with lobectomy can be accomplished with port placement similar to that used for typical thoracoscopic anatomic resections, particularly when the utility incision is close to the region of excision. Generally, chest wall resection precedes lobectomy. Ribs can be transected with Gigli saws, endoscopic shears, or high-speed drills. Division of bone and overlying soft tissue can be planned precisely using thoracoscopic guidance. Isolated primary chest wall masses may require different port position and selective reconstruction using synthetic materials. Patch anchoring can be accomplished by devices that facilitate laparoscopic port site fascial closure., Conclusions: Thoracoscopic chest wall resections have been accomplished safely using tools and maneuvers summarized here. Further outcomes research is necessary to identify the benefits of thoracoscopic chest wall resection over an open approach., (Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
159. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis.
- Author
-
Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A, Demmy TL, Groman A, and Reid M
- Subjects
- Aged, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Female, Humans, Incidence, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Staging, Prognosis, Sarcoma pathology, Sarcoma surgery, Survival Rate, Treatment Outcome, Carcinoma, Non-Small-Cell Lung epidemiology, Lung Neoplasms epidemiology, Sarcoma epidemiology
- Abstract
Background: Sarcomatoid lung carcinomas are unusual, and reports from small single institution case series suggest poor survival rates. We sought to study the clinical characteristics of this form of non-small cell lung cancer using the Surveillance Epidemiology, End Results database., Methods: The Surveillance, Epidemiology, and End Results database was queried for respiratory tract malignancies of sarcomatoid histology. The demographic information and oncologic characteristics of this population were examined. A propensity score-matched analysis of patients was performed to test the hypothesis that patients with sarcomatoid cancers undergoing lobectomies perform worse that those with other non-small cell lung cancers., Results: Of 878,810 patients with lung cancer, only 3,647 patients had a diagnosis of sarcomatoid cancer (0.4%). For the additional analyses of outcomes, only patients with lifetime incidence of a single cancer, known Surveillance, Epidemiology, and End Results historic stage and inpatient reporting were selected (n = 1,921). Demographics, tumor characteristics, and outcomes of these patients were described. Non-small cell lung cancer cohorts (with and without sarcomatoid cancer propensity-matched on age, gender, race, year of diagnosis, grade, and Surveillance, Epidemiology, and End Results historic stage) that underwent lobectomies or pneumonectomies were selected (n = 758). Univariate (hazard ratio, 1.60; 95% confidence interval, 1.31-1.97) and multivariate analysis (hazard ratio, 1.67; 95% confidence interval, 1.36-2.05) revealed a significantly worse overall survival for patients with sarcomatoid cancer compared to matched nonsarcomatoid lung cancer controls., Conclusion: Sarcomatoid cancer is a rare form of lung malignancy with outcomes significantly worse than other forms of non-small cell lung cancer. Novel multimodality treatment strategies are necessary to improve outcomes of this disease., (Copyright © 2012 Mosby, Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
160. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer.
- Author
-
Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, Miller A, and Reid M
- Subjects
- Aged, Carcinoma, Non-Small-Cell Lung surgery, Cohort Studies, Confidence Intervals, Databases, Factual, Disease-Free Survival, Female, Humans, Lung Neoplasms surgery, Lymph Node Excision methods, Lymph Nodes surgery, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness pathology, Neoplasm Staging, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Survival Analysis, Time Factors, Treatment Outcome, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung secondary, Lung Neoplasms mortality, Lung Neoplasms pathology, Lymph Nodes pathology
- Abstract
Background: The non-small cell lung cancer TNM classification system uses only the anatomic extent of lymph node (LN) metastases to define the N category. The number of LNs resected and the ratio of positive LNs to total examined LNs are prognostic in other solid tumors. We used the Surveillance, Epidemiology and End Results database to investigate the effect of these factors on the overall survival of non-small cell lung cancer., Methods: All patients with non-small cell lung cancer in the Surveillance, Epidemiology and End Results database from 1988 through 2007 who had curative resections and had at least one LN examined were included. The prognostic value of age, race, sex, tumor size, histologic grade, number of examined LNs, and ratio of positive LNs to total examined LNs was assessed using a multivariate Cox proportional hazards model for overall survival. The number of LNs examined was categorized into four levels. The percentage of positive LNs was stratified into three levels., Results: Among patients with localized disease, fewer LNs examined corresponded with a worse prognosis. Prognosis improved as more LNs were examined. For patients with regional disease, the differences were significant only at the extremes. Older patients, males, and those with higher grade or larger tumors did worse. Patients with low or moderate ratios of positive to total LNs had better prognoses than those with high ratios., Conclusions: More LNs resected and lower ratios of positive LNs to total examined LNs are associated with better patient survival after non-small cell lung cancer resection independent of age, sex, grade, tumor size, and stage of disease., (Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
161. Advances in lung cancer surgery.
- Author
-
Hennon MW and Yendamuri S
- Abstract
The last few years have witnessed an explosion of the use of minimally invasive techniques for the detection, diagnosis, and treatment of all stages of lung Cancer. The use of these techniques has improved the risk-benefit ratio of surgery and has made it more acceptable to patients considering lung surgery. They have also facilitated the delivery of multi-modality therapy to patients with advanced lung cancer. This review article summarizes current surgical techniques that represent the "cutting edge" of thoracic surgery for lung cancer.
- Published
- 2012
- Full Text
- View/download PDF
162. MicroRNA expression profiles of whole blood in lung adenocarcinoma.
- Author
-
Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, and Vachani A
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma of Lung, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor blood, Biomarkers, Tumor genetics, Female, Humans, Lung Neoplasms diagnosis, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Prognosis, Adenocarcinoma blood, Adenocarcinoma genetics, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Lung Neoplasms blood, Lung Neoplasms genetics, MicroRNAs blood, MicroRNAs genetics
- Abstract
The association of lung cancer with changes in microRNAs in plasma shown in multiple studies suggests a utility for circulating microRNA biomarkers in non-invasive detection of the disease. We examined if presence of lung cancer is reflected in whole blood microRNA expression as well, possibly because of a systemic response. Locked nucleic acid microarrays were used to quantify the global expression of microRNAs in whole blood of 22 patients with lung adenocarcinoma and 23 controls, ten of whom had a radiographically detected non-cancerous lung nodule and the other 13 were at high risk for developing lung cancer because of a smoking history of >20 pack-years. Cases and controls differed significantly for age with a mean difference of 10.7 years, but not for gender, race, smoking history, blood hemoglobin, platelet count, or white blood cell count. Of 1282 quantified human microRNAs, 395 (31%) were identified as expressed in the study's subjects, with 96 (24%) differentially expressed between cases and controls. Classification analyses of microRNA expression data were performed using linear kernel support vector machines (SVM) and top-scoring pairs (TSP) methods, and classifiers to identify presence of lung adenocarcinoma were internally cross-validated. In leave-one-out cross-validation, the TSP classifiers had sensitivity and specificity of 91% and 100%, respectively. The values with SVM were both 91%. In a Monte Carlo cross-validation, average sensitivity and specificity values were 86% and 97%, respectively, with TSP, and 88% and 89%, respectively, with SVM. MicroRNAs miR-190b, miR-630, miR-942, and miR-1284 were the most frequent constituents of the classifiers generated during the analyses. These results suggest that whole blood microRNA expression profiles can be used to distinguish lung cancer cases from clinically relevant controls. Further studies are needed to validate this observation, including in non-adenocarcinomatous lung cancers, and to clarify upon the confounding effect of age.
- Published
- 2012
- Full Text
- View/download PDF
163. Expression of microRNAs in the NCI-60 cancer cell-lines.
- Author
-
Patnaik SK, Dahlgaard J, Mazin W, Kannisto E, Jensen T, Knudsen S, and Yendamuri S
- Subjects
- Cell Line, Tumor, Cluster Analysis, Gene Expression Regulation, Neoplastic radiation effects, Humans, Mutation, Oligonucleotide Array Sequence Analysis, Oncogenes, RNA, Messenger genetics, RNA, Messenger metabolism, Reproducibility of Results, Gene Expression Profiling, MicroRNAs genetics
- Abstract
The NCI-60 panel of 60 human cancer cell-lines of nine different tissues of origin has been extensively characterized in biological, molecular and pharmacological studies. Analyses of data from such studies have provided valuable information for understanding cellular processes and developing strategies for the diagnosis and treatment of cancer. Here, Affymetrix® GeneChip™ miRNA version 1 oligonucleotide microarrays were used to quantify 847 microRNAs to generate an expression dataset of 495 (58.4%) microRNAs that were identified as expressed in at least one cell-line of the NCI-60 panel. Accuracy of the microRNA measurements was partly confirmed by reverse transcription and polymerase chain reaction assays. Similar to that seen among the four existing NCI-60 microRNA datasets, the concordance of the new expression dataset with the other four was modest, with mean Pearson correlation coefficients of 0.37-0.54. In spite of this, comparable results with different datasets were noted in clustering of the cell-lines by their microRNA expression, differential expression of microRNAs by the lines' tissue of origin, and correlation of specific microRNAs with the doubling-time of cells or their radiation sensitivity. Mutation status of the cell-lines for the TP53, PTEN and BRAF but not CDKN2A or KRAS cancer-related genes was found to be associated with changes in expression of specific microRNAs. The microRNA dataset generated here should be valuable to those working in the field of microRNAs as well as in integromic studies of the NCI-60 panel.
- Published
- 2012
- Full Text
- View/download PDF
164. Mediastinal staging of non-small-cell lung cancer.
- Author
-
Dhillon SS, Dhillon JK, and Yendamuri S
- Subjects
- Carcinoma, Non-Small-Cell Lung therapy, Decision Support Techniques, Humans, Lung Neoplasms therapy, Lymphatic Metastasis, Mediastinum, Patient Selection, Predictive Value of Tests, Carcinoma, Non-Small-Cell Lung secondary, Lung Neoplasms pathology, Lymph Nodes pathology, Neoplasm Staging methods
- Abstract
Accurate mediastinal staging is the hallmark of a sound thoracic oncology program. Mediastinal staging remains the most important validated tool for making treatment decisions for patients with non-small-cell lung cancer. The last few years have seen the emergence of several new techniques to improve mediastinal staging. This article summarizes the current state of the art of this rapidly evolving field.
- Published
- 2011
- Full Text
- View/download PDF
165. Safety of thoracoscopic lobectomy in locally advanced lung cancer.
- Author
-
Hennon M, Sahai RK, Yendamuri S, Tan W, Demmy TL, and Nwogu C
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Female, Follow-Up Studies, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Postoperative Complications, Prognosis, Retrospective Studies, Survival Rate, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms surgery, Pneumonectomy, Thoracic Surgery, Video-Assisted, Thoracoscopy
- Abstract
Background: Thoracoscopic lobectomy is well established for the treatment of early non-small cell lung cancer (NSCLC). Its safety and efficacy for advanced-stage disease remain uncertain., Methods: Between January 1, 2002, and July 31, 2007, a total of 125 patients were evaluated for thoracoscopic lobectomy for advanced NSCLC. Thoracoscopic lobectomy was completed in 73 patients. Eleven patients were excluded for extensive chest wall involvement. Open resection was performed in 41 patients, with 19 planned thoracotomies and 22 conversions from an initial thoracoscopic approach., Results: Median operative blood loss, operation time, major complications, and hospital length of stay were all similar for patients undergoing thoracoscopic and open resection. A higher percentage of patients who underwent thoracoscopic lobectomy were able to receive adjuvant therapy compared to the open group (37.2% vs. 5.2%; P = 0.006). The differences between the thoracoscopic and open groups in overall survival (43.7 vs. 22.9 months; P = 0.59) and disease-free survival (34.7 vs. 16.7 months; P = 0.84) were not significant., Conclusions: Thoracoscopic lobectomy for advanced-stage NSCLC can be performed safely, with results equivalent to open techniques. With continued experience, lower morbidity with resections performed for advanced-stage disease by video-assisted thoracoscopic surgery will be expected, similar to that observed with early-stage disease. This is particularly important given the large number of frail patients with advanced-stage disease who require multimodal therapy.
- Published
- 2011
- Full Text
- View/download PDF
166. Is sublobar resection sufficient for carcinoid tumors?
- Author
-
Yendamuri S, Gold D, Jayaprakash V, Dexter E, Nwogu C, and Demmy T
- Subjects
- Carcinoid Tumor mortality, Databases, Factual, Female, Humans, Lung Neoplasms mortality, Male, Middle Aged, Retrospective Studies, SEER Program, Survival Rate, Carcinoid Tumor surgery, Lung Neoplasms surgery, Pneumonectomy methods
- Abstract
Background: The existing guidelines for extent of resection of carcinoid tumors are based on other, more malignant non-small cell lung cancers. Because of the small number of patients in any single institution, we analyzed the Surveillance Epidemiology and End Results (SEER) database to study the effect of the extent of resection of these tumors on overall survival., Methods: All patients with lung cancer in the SEER database from 1973 to 2006 with carcinoid tumors as their only cancer were included. Variables examined included age, race (white, black, others), gender, histologic type (atypical versus typical carcinoid), stage (localized, regional, and distant), extent of resection (sublobar resection, lobectomy, or more extensive) and survival. Univariate analyses (Kaplan-Meier method) were used to select variables for multivariate analysis (Cox regression analysis). Associations were considered significant with an alpha error < 5%. In addition, propensity score-matched Cox regression analysis was performed for patients with typical carcinoid disease., Results: Most patients with carcinoid tumors did not acquire any other cancers (4,785/6,819; 70.2%). Of these, 797 patients had sublobar resection and 2,681 patients had lobectomy or more extensive resections. On univariate analysis, gender (p = 0.014), race (p < 0.001), stage (p < 0.001), histologic type (p < 0.001) and extent of resection (p = 0.04) were associated with overall survival. Multivariate analysis demonstrated that age, gender, race, stage, and histologic type remain statistically associated with overall survival and disease-specific survival, whereas extent of resection is not. Propensity score-matched analysis demonstrates that for typical carcinoid, extent of resection is not associated with overall survival when adjusted for age, gender, race, and stage., Conclusions: Sublobar resection of carcinoid tumors did not compromise oncologic outcomes in a large population-based database. Lobectomy for typical carcinoid tumors is not mandatory as long as complete resection and adequate mediastinal staging are performed., (Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
167. Previous head and neck cancers portend poor prognoses in lung cancer patients.
- Author
-
Jayaprakash V, Cheng C, Reid M, Dexter EU, Nwogu CE, Hicks W, Sullivan M, Demmy TL, and Yendamuri S
- Subjects
- Disease Progression, Female, Follow-Up Studies, Humans, Incidence, Lung Neoplasms etiology, Male, Middle Aged, New York epidemiology, Prognosis, Retrospective Studies, Risk Factors, Survival Rate, Head and Neck Neoplasms therapy, Lung Neoplasms epidemiology, Neoplasms, Second Primary epidemiology, SEER Program
- Abstract
Background: Although a common clinical pairing, the epidemiology and prognosis of lung cancer (LC) after head and neck cancer (HNC) is not well described., Methods: Data from the database of the Surveillance, Epidemiology and End Results (SEER) Program were used to study the epidemiology and survival of patients with LC after HNC. These data were compared with those from our institutional cancer registry., Results: Of all patients with a history of HNC in the SEER database, 8,225 (5%) patients went on to develop LC. This was more than three times the incidence of second primary lung cancers (1.5%). Subsequent LCs in patients with a history of HNC were more common among those with hypopharyngeal and laryngeal cancer and those with localized HNC. Patients with HNC followed by LC had poorer overall survival than did the overall population of patients with LCs in the SEER database. Overall survival after the onset of LC was dismal (median survival, 8 months). Survival was not affected by histologic concordance between HNC and LC. An analysis of 72 patients with LC after HNC reported in our institutional tumor registry over the past 37 years yielded similar results., Conclusions: Of patients who survive LC or HNC, the latter are much more likely to develop a new pulmonary malignancy. Lung cancers that develop after HNC have a poor prognosis. This phenomenon is not explained by misclassified metastases, because histologically discordant cases behave just as poorly. Enhanced surveillance and chemoprevention strategies are needed to detect and prevent subsequent primary LC in survivors of HNC., (Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
168. Lobectomy for patients with limited lung function.
- Author
-
Yendamuri S and Demmy TL
- Subjects
- Humans, Lung Neoplasms rehabilitation, Respiratory Physiological Phenomena, Risk Factors, Smoking Cessation, Time Factors, Lung surgery, Lung Neoplasms surgery, Pneumonectomy methods
- Abstract
Increasingly, lung cancer is being diagnosed at an early stage. This trend is likely to increase with computerized tomographic screening as a result of the findings of the National Lung Screening Trial. Even in 2011, anatomical lobectomy is the gold standard for curative resection for early lung cancer. However, a significant proportion of patients with early lung cancer have limited lung function that places them at higher risk of complications from lobectomy. This article reviews the existing data for lobectomy in patients with limited lung function., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
169. MicroRNA biomarkers in lung cancer: MiRacle or quagMiRe?
- Author
-
Yendamuri S and Kratzke R
- Subjects
- Early Detection of Cancer, Humans, Lung Neoplasms pathology, Microarray Analysis, Nutrition Assessment, Reverse Transcriptase Polymerase Chain Reaction, Biomarkers, Tumor genetics, Lung Neoplasms genetics, MicroRNAs analysis
- Abstract
MicroRNAs have emerged as novel and important regulators of translation. Besides their biological significance, they are being investigated as potential biomarkers of physiological and pathological states. This review article summarizes current investigations of microRNAs as biomarkers in lung cancer. The promises and pitfalls of this exciting new investigational avenue are highlighted., (Copyright © 2011 Mosby, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
170. Thoracoscopic extrapleural pneumonectomy for mesothelioma.
- Author
-
Demmy TL, Platis IE, Nwogu C, and Yendamuri S
- Subjects
- Chemotherapy, Adjuvant, Humans, Lung Neoplasms complications, Lung Neoplasms diagnosis, Male, Mesothelioma complications, Mesothelioma diagnosis, Mesothelioma drug therapy, Mesothelioma radiotherapy, Middle Aged, Pleural Effusion diagnosis, Pleural Effusion etiology, Pleural Neoplasms complications, Pleural Neoplasms diagnosis, Pleural Neoplasms drug therapy, Pleural Neoplasms radiotherapy, Radiotherapy, Adjuvant, Remission Induction, Lung Neoplasms surgery, Mesothelioma surgery, Pleural Neoplasms surgery, Pneumonectomy methods, Thoracoscopy methods
- Abstract
Mesothelioma is the most common primary pleural malignancy. Surgical therapy offers limited cure benefits at the cost of high morbidity. Although technically challenging and performed rarely, a less invasive approach to extrapleural pneumonectomy was developed with the intent to speed convalescence, hasten adjuvant therapies, improve quality of life, and reduce wound surface area for possible tumor contamination., (Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
171. Perioperative outcomes of thoracoscopic anatomic resections in patients with limited pulmonary reserve.
- Author
-
Kachare S, Dexter EU, Nwogu C, Demmy TL, and Yendamuri S
- Subjects
- Aged, Female, Forced Expiratory Volume, Humans, Length of Stay, Lung physiopathology, Male, Middle Aged, New York, Patient Selection, Pneumonectomy adverse effects, Pneumonectomy mortality, Pneumonia etiology, Pneumonia prevention & control, Practice Guidelines as Topic, Predictive Value of Tests, Pulmonary Diffusing Capacity, Respiratory Function Tests, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Lung surgery, Pneumonectomy methods, Thoracic Surgery, Video-Assisted adverse effects, Thoracic Surgery, Video-Assisted mortality
- Abstract
Background: Preoperative pulmonary function tests are used to assess operability for either lobectomy or pneumonectomy. Current guidelines for defining high-risk patients for anatomic lung resection on the basis of these tests were developed in the era of open thoracotomy. We studied the outcomes of such high-risk patients after video-assisted thoracoscopic surgical resections to assess the performance of these guidelines., Methods: Records of all patients who underwent anatomic resection from 2001 to 2009 at a single institution were queried for pulmonary function and perioperative outcomes. Patients with predicted postoperative forced expiratory volume in 1 second or predicted postoperative lung carbon dioxide diffusing capacity less than 40% were considered to have limited pulmonary reserve. Perioperative outcomes of patients with limited pulmonary reserve who underwent thoracoscopic resection were documented and compared with those of similar patients who underwent open resection., Results: Of 600 patients assessed, 70 had limited pulmonary reserve according to our criteria. Forty-seven of them underwent thoracoscopic resection. This cohort had excellent outcomes, with mortality of 2.1%, pneumonia rate of 4.3%, and discharge independence rate of 95.7%. Relative to contemporary patients undergoing open resection (N=23, including 12 conversions), patients undergoing thoracoscopic resection had lower incidence of pneumonia (4.3% vs. 21.7%, P<.05) and shorter intensive care unit stay (2 vs 4 days, P=.05)., Conclusions: Patients with marginal lung function tolerate thoracoscopic anatomic resection well. Reassessment of the traditional pulmonary function test guidelines for operability is warranted in the current era of thoracoscopic lung surgery., (Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
172. Does circular stapled esophagogastric anastomotic size affect the incidence of postoperative strictures?
- Author
-
Yendamuri S, Gutierrez L, Oni A, Mashtare T, Khushalani N, Yang G, Nava H, Demmy T, and Nwogu C
- Subjects
- Adult, Aged, Aged, 80 and over, Anastomosis, Surgical methods, Anastomotic Leak epidemiology, Constriction, Pathologic, Female, Humans, Incidence, Male, Middle Aged, Anastomosis, Surgical adverse effects, Esophagectomy adverse effects, Postoperative Complications epidemiology, Surgical Staplers
- Abstract
Background: Postoperative anastomotic strictures produce significant morbidity after esophagectomy. Previous reports have described a variable association between the diameter of the circular end-to-end anastomosis (EEA) stapler commonly used in esophagogastric anastomoses and the incidence of stricture formation. Stapler technology has improved. We investigated an association between stapler diameter and the incidence of postoperative anastomotic strictures in a contemporary series. This has renewed importance given the limited diameter of trans-oral staplers that are being increasingly used., Methods: Retrospective chart review revealed that of 194 patients undergoing an esophagectomy over a 10-y period (10/1998-8/2008) at our institution, an EEA stapler was used in 91. EEA size information and follow-up were available in 89 patients. Patients were divided into two groups based on EEA size: 'small' = 23-25 mm (n = 24) and 'large' = 28-33 mm (n = 65). Patients with strictures were identified based on symptoms of dysphagia requiring an esophageal dilation procedure. Patients with postoperative leaks were excluded when analyzing for the association of stricture with EEA size, as postoperative leaks are known to be associated with stricture. Wilcoxon and Fisher's exact tests were used for statistical analysis; a 5% α error was accepted., Results: Fifteen (16.8%) of 89 patients developed a stricture postoperatively. The anastomotic leak rate was 3.3%. There was no statistically significant association between EEA size group and stricture formation (P = 0.7506)., Conclusions: No association was found between the size of the EEA stapler used and stricture formation. EEA size should be determined at surgery by the native esophageal diameter., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
173. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells.
- Author
-
Patnaik SK, Kannisto E, Mallick R, and Yendamuri S
- Subjects
- Cell Line, Tumor, Cell Movement genetics, Cell Proliferation, Epithelial Cells metabolism, Epithelial Cells pathology, Genes, Neoplasm genetics, Humans, MicroRNAs metabolism, Neoplasm Invasiveness, Phenotype, Prognosis, Stromal Cells metabolism, Stromal Cells pathology, Tumor Stem Cell Assay, Gene Expression Regulation, Neoplastic, Lung Neoplasms genetics, Lung Neoplasms pathology, MicroRNAs genetics
- Abstract
Introduction: Expression levels of miR-146b-5p and -3p microRNAs in human non-small cell lung cancer (NSCLC) are associated with recurrence of the disease after surgery. To understand this, the effect of miR-146b overexpression was studied in A549 human lung cancer cells., Methods: A549 cells, engineered with lentiviruses to overexpress the human pre-miR-146b precursor microRNA, were examined for proliferation, colony formation on plastic surface and in soft agar, migration and invasiveness in cell culture and in vivo in mice, chemosensitivity to cisplatin and doxorubicin, and global gene expression. miR-146b expressions were assessed in microdissected stroma and epithelia of human NSCLC tumors. Association of miR-146b-5p and -3p expression in early stage NSCLC with recurrence was analyzed., Principal Findings: A549 pre-miR-146b-overexpressors had 3-8-fold higher levels of both miR-146b microRNAs than control cells. Overexpression did not alter cellular proliferation, chemosensitivity, migration, or invasiveness; affected only 0.3% of the mRNA transcriptome; and, reduced the ability to form colonies in vitro by 25%. In human NSCLC tumors, expression of both miR-146b microRNAs was 7-10-fold higher in stroma than in cancerous epithelia, and higher miR-146b-5p but lower -3p levels were predictive of recurrence., Conclusions: Only a minimal effect of pre-miR-146b overexpression on the malignant phenotype was seen in A549 cells. This could be because of opposing effects of miR-146b-5p and -3p overexpression as suggested by the conflicting recurrence-predictive values of the two microRNAs, or because miR-146b expression changes in non-cancerous stroma and not cancerous epithelia of tumors are responsible for the prognostic value of miR-146b.
- Published
- 2011
- Full Text
- View/download PDF
174. MicroRNAs and prognosis of lung cancer.
- Author
-
Yendamuri S
- Subjects
- Disease Progression, Genetic Markers, Humans, Lung Neoplasms pathology, Prognosis, Lung Neoplasms genetics, MicroRNAs genetics
- Abstract
MicroRNAs have recently emerged as important regulatory molecules of normal and abnormal cellular behavior. They are small (18-22 nucleotides) noncoding RNA that control translation by sequence complementarity of their "seed" sequence to the 3' untranslated regions (UTR) of their target mRNAs, which are RNA species that code for proteins. Apart from their biological importance, these small molecules have received attention as biomarkers because of their remarkable stability in tissues and body fluids and the ease of their measurement. A recent article in Cancer Research by Voortman et al has failed to validate the hypothesis that tumor microRNA expression is associated with prognosis. In light of this significant finding, this article summarizes the current state of the art of microRNA biomarkers for the prognostication of lung cancer., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
175. Detection of microRNAs in dried serum blots.
- Author
-
Patnaik SK, Mallick R, and Yendamuri S
- Subjects
- Freezing, Temperature, MicroRNAs blood, Polymerase Chain Reaction methods
- Abstract
We observed the preservation of microRNAs in unrefrigerated dried serum blots. Preservation was not adversely affected by drying or storing at 37, 45, or 60°C instead of room temperature, but it was harmed when blots were dried incompletely before storage. Preservation of microRNAs in serum was not diminished if, instead of being kept frozen at -80°C, it was stored as dried blots at room temperature for 5 months or at 37°C for 4 weeks. Thus, dried blots can be a convenient and safer way to save, transport, and store serum for microRNA assays., (Published by Elsevier Inc.)
- Published
- 2010
- Full Text
- View/download PDF
176. MicroRNAs and esophageal cancer.
- Author
-
Patnaik SK, Mallick R, and Yendamuri S
- Abstract
Cancer of the esophagus is a highly aggressive disease associated with an overall poor prognosis. There is an insistent need for improving our understanding of the molecular basis of this disease. The recent emergence of observations on the role of microRNAs in cancer and their potential as biomarkers has prompted many investigations to examine their relevance to esophageal cancer. This article provides an introduction to microRNA biology and the techniques involved in studying them, and summates what is now known about their role and utility in regard to neoplastic esophageal diseases.
- Published
- 2010
- Full Text
- View/download PDF
177. Aorto-esophageal fistula: a rare fatal case caused by esophageal malignancy.
- Author
-
Lee RY, Flaherty L, Khushalani NI, Kanehira K, Nwogu C, Yendamuri S, Nava HR, and Yang GY
- Published
- 2010
- Full Text
- View/download PDF
178. MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis.
- Author
-
Mallick R, Patnaik SK, and Yendamuri S
- Abstract
MicroRNAs are tiny non-coding RNA molecules which play important roles in the epigenetic control of cellular processes by preventing the translation of proteins from messenger RNAs (mRNAs). A single microRNA can target different mRNAs, and an mRNA can be targeted by multiple microRNAs. Such complex interplays underlie many molecular pathways in cells, and specific roles for many microRNAs in physiological as well as pathological phenomena have been identified. Changes in expression of microRNAs have been associated with a wide variety of disease conditions, and microRNA-based biomarkers are being developed for the identification and monitoring of such states. This review provides a general overview of the current state of knowledge about the biology of microRNAs, and specific information about microRNAs with regard to the diagnosis and prognosis of lung cancer.
- Published
- 2010
- Full Text
- View/download PDF
179. Analysis of second primary lung cancers in the SEER database.
- Author
-
Bhaskarla A, Tang PC, Mashtare T, Nwogu CE, Demmy TL, Adjei AA, Reid ME, and Yendamuri S
- Subjects
- Aged, Female, Humans, Incidence, Male, SEER Program, Survival Rate, United States epidemiology, Carcinoma epidemiology, Lung Neoplasms epidemiology, Neoplasms, Second Primary epidemiology
- Abstract
Background: We sought to examine the outcomes of second primary lung cancers in the large population-based Surveillance Epidemiology and End Results (SEER) database. We also sought to study the outcomes of synchronous second non-small-cell lung cancers (NSCLCs), classified as stage IVA (M1A) according to the seventh edition of the TNM staging for lung cancer., Methods: Data of patients with at least two primary lung cancers were obtained. All available variables potentially associated with the incidence of a second primary lung cancer were examined. The overall survival of patients with synchronous NSCLC was compared with those with metachronous and stage IV NSCLC., Results: A small proportion (1.5%) of patients with lung cancer developed a second primary. A second primary is associated with younger age, female gender, earlier stage, and white race. The median survival of patients with metachronous NSCLCs (n = 3352) was worse than those with synchronous NSCLCs (n = 1858) (median survival 22 mo versus 29 mo, respectively; P < 0.01). After adjusting for age, race, gender, stage, and histology of both primaries, this difference in survival between patients with synchronous and metachronous second primary lung cancers was not statistically significant, but was better than those with stage IV NSCLC (n = 127,654; median survival 4 mo)., Conclusions: The incidence of second primary lung cancer is lower than that previously reported. Factors associated with good prognosis predict a second primary. Synchronous NSCLCs have an outcome better than a stage IV (M1a) designation. These patients should receive appropriate stage-specific multi-modality therapy suitable for the independent stage of each cancer without considering them unresectable., ((c) 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
180. Does thoracoscopic pneumonectomy for lung cancer affect survival?
- Author
-
Nwogu CE, Yendamuri S, and Demmy TL
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Time Factors, Lung Neoplasms mortality, Lung Neoplasms surgery, Pneumonectomy methods, Thoracoscopy
- Abstract
Background: Although thoracoscopic pneumonectomy may be performed safely, its effect on survival is unknown., Methods: Seventy patients underwent elective pneumonectomy for malignancy at a comprehensive cancer center (Roswell Park Cancer Institute, Buffalo, NY) from 2002 to 2008. Using the same incision set as thoracoscopic lobectomy, candidates for a thoracoscopic pneumonectomy had adequate hilar visualization using flexible thoracoscopy, tissue control using novel retractors, and intrapericardial exposure when appropriate. The bronchus was divided last to prevent excessive traction on the main pulmonary artery., Results: Thirty-four percent of patients had neoadjuvant therapy, proportionally distributed among groups. Patients in the thoracoscopic group had shorter lengths of stay in the hospital and less operative blood loss. Eight patients who were converted to thoracotomy had significantly more operative blood loss. The complication rates were similar among thoracoscopic, converted, and open groups. For both the thoracoscopic and open groups there was 1 death before 30 days. Between 30 and 90 days there was 1 death in the thoracoscopic group as a result of disease progression and 2 deaths in the open group as a result of cardiovascular causes. There was a modest improvement in overall survival in the video-assisted thoracic surgery group relative to the thoracotomy group, but the former group had smaller tumors. When stratified by stage, there was no survival difference., Conclusions: Pneumonectomy performed either by means of thoracoscopy or thoracotomy resulted in equivalent survival. Further studies and follow-up are needed to verify the benefits of video-assisted thoracic surgery pneumonectomy for lung cancer., (2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
181. Thoracoscopic chest wall resection: what is its role?
- Author
-
Demmy TL, Nwogu CE, and Yendamuri S
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Lung Neoplasms surgery, Pneumonectomy methods, Thoracic Wall surgery, Thoracoscopy
- Abstract
Background: Although thoracoscopic operations like pulmonary lobectomy are gaining popularity because of reduced complications and improved quality of life, the role of more complex procedures is unknown., Methods: From January 2007 to April 2009, 3 patients (2 women) aged 61, 71, and 79 years, underwent thoracoscopic lobectomy with en bloc chest wall resection in an attempt to reduce perioperative morbidity. During the same time, 4 additional patients underwent thoracoscopic explorations before open en bloc resections and 10 underwent thoracotomy to remove primary or secondary chest wall neoplasms. Innovations that facilitated the thoracoscopic operations were the use of an endoscopic rib cutter and division of other chest wall tissues with thermal sealing technology., Results: Tumors were stage IIb-IIIa and sized 3.2 to 5 cm. Two patients received neoadjuvant therapy before resection. No patients required reconstruction. The first patient required thoracoscopic reexploration to evacuate a hematoma attributed to aggressive anticoagulation required because of high-risk cardiac comorbidities. No other complications occurred. By 3 weeks after resection, the first patient had discontinued narcotics, and the other patients denied pain and analgesic use entirely. All patients were alive, with no evidence of disease, at 26, 16, and 6 months after their operations., Conclusions: Highly selected cases of lung cancer with chest wall extension are appropriate candidates for thoracoscopic resection. Advanced thoracoscopic instrumentation makes this procedure feasible while following oncologic principles., (2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
182. Overexpression of microRNA miR-30a or miR-191 in A549 lung cancer or BEAS-2B normal lung cell lines does not alter phenotype.
- Author
-
Patnaik SK, Kannisto E, and Yendamuri S
- Subjects
- Animals, Antineoplastic Agents pharmacology, Cell Cycle drug effects, Cell Cycle genetics, Cell Line, Cell Line, Tumor, Cell Survival drug effects, Cell Survival genetics, Cell Survival physiology, Cisplatin pharmacology, Doxorubicin pharmacology, Flow Cytometry, Gene Expression, Humans, Lung cytology, Lung metabolism, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Mice, Mice, SCID, Neoplasms, Experimental drug therapy, Neoplasms, Experimental genetics, Neoplasms, Experimental pathology, Reverse Transcriptase Polymerase Chain Reaction, Transfection, Transplantation, Heterologous, Cell Cycle physiology, Cell Proliferation, Lung Neoplasms pathology, MicroRNAs genetics
- Abstract
Background: MicroRNAs (miRNAs) are small, noncoding RNAs (ribonucleic acids) that regulate translation. Several miRNAs have been shown to be altered in whole cancer tissue compared to normal tissue when quantified by microarray. Based on previous such evidence of differential expression, we chose to study the functional significance of miRNAs miR-30a and -191 alterations in human lung cancer., Methodology/principal Findings: The functional significance of miRNAs miR-30a and -191 was studied by creating stable transfectants of the lung adenocarcinoma cell line A549 and the immortalized bronchial epithelial cell line BEAS-2B with modest overexpression of miR-30a or -191 using a lentiviral system. When compared to the corresponding controls, both cell lines overexpressing miR-30a or -191 do not demonstrate any significant changes in cell cycle distribution, cell proliferation, adherent colony formation, soft agar colony formation, xenograft formation in a subcutaneous SCID mouse model, and drug sensitivity to doxorubicin and cisplatin. There is a modest increase in cell migration in cell lines overexpressing miR-30a compared to their controls., Conclusions/significance: Overexpression of miR-30a or -191 does not lead to an alteration in cell cycle, proliferation, xenograft formation, and chemosensitivity of A549 and BEAS-2B cell lines. Using microarray data from whole tumors to select specific miRNAs for functional study may be a suboptimal strategy.
- Published
- 2010
- Full Text
- View/download PDF
183. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
- Author
-
Patnaik SK, Kannisto E, Knudsen S, and Yendamuri S
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Female, Gene Expression, Humans, In Situ Hybridization, Kaplan-Meier Estimate, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, MicroRNAs genetics, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Carcinoma, Non-Small-Cell Lung genetics, Gene Expression Profiling methods, Lung Neoplasms genetics, MicroRNAs biosynthesis, Neoplasm Recurrence, Local genetics
- Abstract
Prognostic markers that can predict the relapse of localized non-small cell lung cancer (NSCLC) have yet to be defined. We surveyed expression profiles of microRNA (miRNA) in stage I NSCLC to identify patterns that might predict recurrence after surgical resection of this common deadly cancer. Small RNAs extracted from formalin-fixed and paraffin-embedded tissues were hybridized to locked nucleic acid probes against 752 human miRNAs (representing 82% of the miRNAs in the miRBase 13.0 database) to obtain expression profiles for 37 cases with recurrence and 40 cases without recurrence (with clinical follow-up for at least 32 months). Differential expression between the two case groups was detected for 49% of the miRNAs (Wilcoxon rank sum test; P<0.01). The performance of expression profiles at differentiating the two case groups was assessed by leave-one-out and Monte Carlo cross-validations. In leave-one-out cross-validation using support vector machines- or top-scoring gene pair classifier methods, which looked for six- or two-miRNA-based classifiers, the identified miRNA expression pattern predicted recurrence with an accuracy of 70% and 83%, and hazard ratio of 3.6 [95% confidence interval (95% CI), 1.8-7.1] and 9.0 (95% CI, 4.4-18.2), respectively. Mean accuracy in Monte Carlo cross-validation using 1,000 random 60-17 splits was 69% (95% CI, 68-70) and 72% (95% CI, 71-72), respectively. The specific miRNAs mir-200b*, mir-30c-1*, mir-510, mir-630, mir-657, and mir-146b-3p and mir-124*, mir-585, and mir-708, respectively, represented most commonly among the 1,000 classifiers identified in Monte Carlo cross-validation by the two methods. MiRNAs mir-488, mir-503, and mir-647 were identified as potential reference miRNAs for future studies, based on the stability of their expression patterns across the 77 cases and the two case-groups. Our findings reinforce efforts to profile miRNA expression patterns for better prognostication of stage I NSCLC.
- Published
- 2010
- Full Text
- View/download PDF
184. Is thoracoscopic pneumonectomy safe?
- Author
-
Sahai RK, Nwogu CE, Yendamuri S, Tan W, Wilding GE, and Demmy TL
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Incidence, Lung Neoplasms diagnosis, Lung Neoplasms mortality, Male, Middle Aged, New York epidemiology, Postoperative Complications epidemiology, Respiratory Function Tests, Retrospective Studies, Risk Factors, Survival Rate trends, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed, Lung Neoplasms surgery, Pneumonectomy methods, Thoracoscopy methods
- Abstract
Background: While thoracoscopic surgical lobectomy is an established operation, the safety of thoracoscopic pneumonectomy (TP) is uncertain., Methods: From January 1, 2002, to September 30, 2008 at a comprehensive cancer center, 70 patients underwent pneumonectomy. Three patients were excluded for emergent operations. Thoracoscopic pneumonectomy was completed successfully in 24 patients and attempted in 8 others (25% conversion rate). Analysis was done on an intention-to-treat basis., Results: By 2008, 75% of pneumonectomy cases were planned as TP while there were no conversions to thoracotomy. There was no difference in median blood loss between patients undergoing TP versus thoracotomy (325 vs 300 mL, p = 0.52), but operations were longer (286 vs 228 minutes, p < 0.01). Median intensive care unit stay was 2 days in both groups and median hospital stay was 5.0 days in the TP group versus 6.0 days in the thoracotomy group (p = 0.28). Major complications were similar between groups. The TP reoperations were for bleeding (2), bronchopleural fistula (2), empyema (1), and chylothorax (1). The only TP death occurred in an 83-year-old patient from respiratory failure. Neither the use of adjuvant therapy nor the time between surgery and commencement of adjuvant therapy was different between groups. Conversions alone compared with patients undergoing thoracotomy were associated with a moderate increase in blood loss and intensive care unit stay, but not in any major complications., Conclusions: Thoracoscopic pneumonectomy can be done safely. The availability of this option is important especially in an era of multimodality therapy as more debilitated patients present for surgical therapy.
- Published
- 2009
- Full Text
- View/download PDF
185. Lung cancer xenografting alters microRNA profile but not immunophenotype.
- Author
-
Bogner PN, Patnaik SK, Pitoniak R, Kannisto E, Repasky E, Hylander B, Yendamuri S, and Ramnath N
- Subjects
- Animals, Gene Expression Profiling, Mice, Mice, SCID, Lung Neoplasms genetics, MicroRNAs genetics, Xenograft Model Antitumor Assays
- Abstract
Lung tumor xenografts grown in immunocompromised mice provide a renewable source of tumor tissue for research and a means to study individualized response to chemotherapy. Critical to this utility is verification that the xenograft cells retain core phenotypic characteristics of the original tumor. We compared eight non-small cell lung carcinomas with their corresponding xenografts grown in mice with severe combined immunodeficiency by way of histology, immunohistochemistry, and microRNA expression profiling. Six of the eight xenografts closely resembled their original tumor by light microscopy. The xenografts also largely retained key immunophenotypic features. With expression profiling of human microRNAs, however, xenografts clustered separately from the original tumors. While this may be partly due to contamination by non-neoplastic human and mouse stroma, the results suggest that miRNA expression may be altered in xenografts and that this possibility should be further evaluated.
- Published
- 2009
- Full Text
- View/download PDF
186. Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).
- Author
-
Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N, and Adjei AA
- Subjects
- Aged, Animals, Dogs, Female, Fluoroscopy, Humans, Male, Middle Aged, Antineoplastic Agents administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Chemotherapy, Cancer, Regional Perfusion methods, Cisplatin administration & dosage, Lung Neoplasms drug therapy, Lung Neoplasms surgery, Thoracoscopy
- Abstract
Background: After promising preclinical studies using a thoracoscopic regional lung chemotherapy technique less morbid than open perfusion methods, we initiated a Phase I clinical study., Methods: Four performance status 0 to 1 patients with oligometastatic stage IV lung cancer underwent unilateral thoracoscopic lung suffusion targeting the bulk of primary disease and regional lymph nodes. We used the term suffusion (permeation of an organ) to describe the total lung distribution of chemotherapy afforded by venous distention akin to retrograde cardioplegia physiology. This was obtained by temporary thoracoscopic pulmonary vein occlusions and fluoroscopy-guided transfemoral intravascular balloon occlusion, drainage, and cisplatin distention of the main pulmonary artery. Single-lung ventilation allowed atelectasis that helped to drain the blood under pulmonary artery occlusion, then cisplatin (5% systemic dose) was instilled during venous occlusion and lung reexpansion. Chemotherapy dwelled for 30 minutes before lung reperfusion., Results: All four suffusions were successful (three right, one left). Cisplatin remained concentrated in the pulmonary circulation by the end of the dwell (1,124 versus 236 ng/mL systemic). There were no changes in the postsuffusion pulmonary function tests or lung perfusion scans. All patients were discharged early (24 to 48 hours) without chest tubes, began standard chemotherapy without delay, and completed follow-up. After two systemic chemotherapeutic cycles primary tumors had volume reductions of 96%, 88%, 64%, and 14%, with the latter showing a 100% volume increase in a nonsuffused osseous metastasis., Conclusions: Our initial clinical experience of thoracoscopic lung suffusion suggests that this approach is safe and merits future study with higher dose levels.
- Published
- 2009
- Full Text
- View/download PDF
187. Chest tube-delivered bupivacaine improves pain and decreases opioid use after thoracoscopy.
- Author
-
Demmy TL, Nwogu C, Solan P, Yendamuri S, Wilding G, and DeLeon O
- Subjects
- Aged, Analgesia, Patient-Controlled, Analgesics, Opioid administration & dosage, Chest Tubes, Female, Fentanyl administration & dosage, Humans, Male, Middle Aged, Pain Measurement, Prospective Studies, Anesthetics, Local, Bupivacaine, Interpleural Analgesia, Pain, Postoperative drug therapy, Thoracoscopy
- Abstract
Background: This study compared a simplified method of intrapleural bupivacaine administration with traditional analgesic therapy to decrease postoperative pain and opioid usage in patients after thoracoscopy., Methods: Thirty patients who had non-rib-spreading thoracoscopic operations under general anesthesia were prospectively randomized to no local anesthetic infusion (control), intermittent bolus (30 mL every 6 hours), or continuous infusion (5 mL/h). Bupivacaine (0.25%) was delivered through the pleural infusion channel of a specially designed single silicone 28F chest tube. Total intravenous fentanyl patient-controlled analgesia (boluses with basal rate) infused in the first 24 hours postoperatively was the designated primary study end point. Escalations of analgesic therapy, including ketorolac administration, were standardized across all groups. Nurses assessed pain control at onset and every 6 hours by visual analog pain scales (VAPS, 100 mm). VAPS were repeated 10 minutes later to assess any opioid or bupivacaine bolus effects., Results: No study-related adverse events occurred. Compared with controls, pooled VAPS scores and 24-hour fentanyl consumption were significantly lower for the intermittent and continuous administration groups (1753 vs 1180 vs 1177 microg/24 h, respective median; p = 0.04) Early (6-hour) VAPS analgesic responses were more certain for intermittent (10 of 10) and continuous (10 of 10) patients than controls (7 of 10, p = .04). Five continuous patients successfully maintained VAPS scores below 20 mm throughout the study vs 3 intermittent and 2 controls (p = .045)., Conclusions: Intermittent or continuous intrapleural bupivacaine infused through the chest tube reliably reduces postoperative pain and 24-hour opioid usage in thoracoscopy patients.
- Published
- 2009
- Full Text
- View/download PDF
188. Thoracoscopic lobectomy with chest wall resection after neoadjuvant therapy.
- Author
-
Yendamuri S, Nwogu CE, and Demmy TL
- Abstract
Chest wall involvement from lung malignancy presents technical challenges for a minimally invasive surgical approach. Recently, new thoracoscopic rib cutting instrumentation has been developed and may offer a safe and efficient resection. Compared with thoracotomy, thoracoscopic lung and chest wall resection may potentially lower the morbidity associated with chest wall resection by thoracotomy. We present a case of thoracoscopic lobectomy with an en bloc chest wall resection.
- Published
- 2009
- Full Text
- View/download PDF
189. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC).
- Author
-
Yendamuri S, Vaporciyan AA, Zaidi T, Feng L, Fernandez R, Bekele NB, Hofstetter WL, Jiang F, Mehran RJ, Rice DC, Spitz MR, Swisher SG, Walsh GL, Roth JA, and Katz RL
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma genetics, Adult, Aged, Aged, 80 and over, Bronchi pathology, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell genetics, Cell Differentiation, Cohort Studies, Early Diagnosis, Female, Humans, Lung Neoplasms genetics, Male, Middle Aged, Neoplasm Staging, Prognosis, Survival Rate, Carcinoma, Non-Small-Cell Lung diagnosis, Chromosome Deletion, Chromosomes, Human, Pair 10 genetics, Chromosomes, Human, Pair 3 genetics, In Situ Hybridization, Fluorescence methods, Lung Neoplasms diagnosis
- Abstract
Background: Our objective was to study the feasibility of detecting chromosomal deletions at 3p22.1 and 10q22.3 by fluorescent in situ hybridization (FISH) and to examine their distribution in different areas of the airway in patients with non-small cell lung cancer., Methods: Brush biopsies from the mainstem bronchus on the normal side contralateral to the tumor (NBB) and mainstem bronchus on the tumor side (TBB) were obtained from 122 patients who underwent surgical resection. Touch preparations from the tumor (TTP), normal lung parenchyma, and bronchi adjacent to the tumor were also obtained. Two FISH assays using probes complementary to 3p22.1 and 10q22.3 were used to detect deletions., Results: NBB showed a relatively low deletion rate of 3p22.1 and 10q22.3 compared with TTP (p < 0.0001). TBB showed a significantly higher rate of deletions compared with NBB but lower than TTP from the tumor (p < 0.05) for both 3p22.1 and 10q22.3. A significantly higher deletion rate was seen at TTP compared with normal lung parenchyma at both the 3p22.1 and 10 q22.3 (p < 0.0001). Correlations were seen between the deletion rates of TTP and TBB at 3p22.1 (rho = 0.61, p < 0.0001) and between TTP and bronchi adjacent to the tumor at 10q22.3 (rho = 0.64, p < 0.0001)., Conclusion: Deletions of the 3p22.1 and 10q22.3 regions can be reliably detected by FISH. As one progresses from the contralateral normal bronchus to the bronchus on the side of tumor and the tumor itself, the percentage of chromosomal deletions increases in a statistically significant fashion. This suggests that, FISH analysis of bronchoscopic brushes may be useful for identifying patients at high risk for developing non-small cell lung cancer.
- Published
- 2008
- Full Text
- View/download PDF
190. ARLTS1 - a novel tumor suppressor gene.
- Author
-
Yendamuri S, Trapasso F, and Calin GA
- Subjects
- Gene Expression Profiling, Genetic Predisposition to Disease, Humans, ADP-Ribosylation Factors genetics, Genes, Tumor Suppressor, Lung Neoplasms genetics, Polymorphism, Genetic
- Abstract
ARLTS1 (ADP-ribosylation factor-like tumor suppressor gene 1) is a member of the ARF family of the Ras superfamily of small GTPases that are known to be involved in multiple regulatory pathways altered in human carcinogenesis. Here, we review recent work that has provided insights into the role of this small gene as an emerging player in both familial and sporadic cancers of several histotypes. ARLTS1 is a low penetrance gene that is primarily dysregulated in sporadic lung cancer by promoter hypermethylation. Two ARLTS1 polymorphisms are also associated with familial cancer risk. Down-regulation of ARLTS1 is seen in all lung cancer cell lines studied and in a significant proportion (37%) of primary lung tumors. Restoration of ARLTS1 expression in ARLTS1-deficient lung cancer cell lines by either demethylation or adenoviral transduction leads to apoptosis via caspase-dependent mechanisms. Furthermore, ARLTS1 re-expression induces an in vivo decreased tumor growth in preclinical models of lung cancer. Microarray analysis of gene expression patterns in cells transduced with ARLTS1 demonstrates that various pathways involved in cell survival, proliferation and development mediate its pro-apoptotic effects.
- Published
- 2008
- Full Text
- View/download PDF
191. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer.
- Author
-
Yendamuri S, Komaki RR, Correa AM, Allen P, Wynn B, Blackmon S, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, and Mehran RJ
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung pathology, Costs and Cost Analysis, Disease-Free Survival, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Radiotherapy Dosage, Retrospective Studies, Survival Rate, Treatment Outcome, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Radiotherapy, Conformal
- Abstract
Introduction: Anatomic resection is currently the standard of care for patients with stage I non-small cell lung cancer (NSCLC). Some stage I patients are unable to tolerate lobectomy because of limited lung function or prohibitive comorbidities. In this study, we retrospectively compared the outcome of patients treated with wedge resection or three-dimensional (3-D) conformal radiation therapy, the most common treatment modalities used for such high-risk patients., Methods: All patients with stage I NSCLC from 1988 to 2005 who were not considered candidates for anatomic surgical resection were reviewed. Univariate and multivariate analyses were performed to assess the influence of 3-D conformal radiation and surgery on overall survival and recurrence-free survival. Propensity score-matched analysis and cost assessments were performed to compare outcomes with both modalities. Propensity matching was performed for gender, histology, tumor size, performance status, and age., Results: Of 160 patients studied, 68 patients received limited resection and 92 patients received 3-D conformal radiation. Univariate and multivariate analyses suggested a trend toward improved outcome in limited resection. Propensity matching was performed with 34 matched pairs and demonstrated no statistically significant difference in overall survival or recurrence-free survival. The mean cost of radiation therapy ($32,735) was not statistically significantly different from surgery ($30,411)., Conclusion: In high-risk patients with NSCLC, limited resection has a tendency towards improved outcome. A propensity matched analysis did not show a clear benefit for limited resection, which may be due in part to an inadequate number of patients for analysis and/or increased comorbidities of patients treated with 3-D conformal radiation.
- Published
- 2007
- Full Text
- View/download PDF
192. Tumor suppressor functions of ARLTS1 in lung cancers.
- Author
-
Yendamuri S, Trapasso F, Ferracin M, Cesari R, Sevignani C, Shimizu M, Rattan S, Kuroki T, Dumon KR, Bullrich F, Liu CG, Negrini M, Williams NN, Kaiser LR, Croce CM, and Calin GA
- Subjects
- ADP-Ribosylation Factors biosynthesis, Adenoviridae genetics, Amino Acid Sequence, Animals, Apoptosis genetics, Cell Growth Processes genetics, Cell Line, Tumor, Conserved Sequence, DNA Methylation, Down-Regulation, Genetic Therapy methods, Humans, Lung Neoplasms metabolism, Lung Neoplasms therapy, Mice, Mice, Nude, Molecular Sequence Data, Promoter Regions, Genetic, Sequence Alignment, ADP-Ribosylation Factors genetics, Genes, Tumor Suppressor, Lung Neoplasms genetics
- Abstract
ARLTS1 is a newly characterized tumor suppressor gene located at chromosome 13q14.3 and involved in the pathogenesis of various types of tumors: two single-nucleotide polymorphisms, one of them responsible for protein truncation, were found statistically associated with familial malignancies, whereas DNA hypermethylation and genomic deletions have been identified as a mechanism of ARLTS1 down-regulation in sporadic cancers. We found that in a large portion of lung carcinomas (37%) and in all analyzed lung cancer cell lines, ARLTS1 is strongly down-regulated due to DNA methylation in its promoter region. After its restoration by adenoviral transduction, ARLTS1-negative A549 and H1299 cells underwent apoptosis and inhibition of cell growth. Furthermore, ARLTS1 reexpression significantly reduced the ability of A549 and H1299 to form tumors in nude mice. Finally, we identified approximately 650 transcripts differentially expressed after restoration of ARLTS1 expression in A549 cells, suggesting that various pathways involved in cell survival, proliferation, signaling, and development mediate the effects of wild-type ARLTS1 in a lung cancer system.
- Published
- 2007
- Full Text
- View/download PDF
193. Right-to-left interatrial shunt with hypoxemia caused by a right atrial thrombus.
- Author
-
Vargas-Beal F, Coulter SA, Yendamuri S, Contreras A, and Duncan JM
- Subjects
- Anticoagulants therapeutic use, Blood Pressure, Cardiac Surgical Procedures, Cardiopulmonary Bypass, Echocardiography, Doppler, Color, Echocardiography, Transesophageal, Heart Atria diagnostic imaging, Heart Atria physiopathology, Heart Diseases diagnostic imaging, Heart Diseases etiology, Heart Diseases physiopathology, Heart Diseases surgery, Heart Septal Defects, Atrial diagnosis, Heart Septal Defects, Atrial physiopathology, Heart Septal Defects, Atrial surgery, Humans, Hypoxia diagnostic imaging, Hypoxia physiopathology, Male, Middle Aged, Protein C Deficiency diagnosis, Protein C Deficiency drug therapy, Pulmonary Artery physiopathology, Thrombectomy, Thrombosis diagnostic imaging, Thrombosis etiology, Thrombosis physiopathology, Thrombosis surgery, Treatment Outcome, Warfarin therapeutic use, Catheterization, Central Venous adverse effects, Coronary Circulation, Heart Diseases complications, Heart Septal Defects, Atrial complications, Hypoxia etiology, Protein C Deficiency complications, Thrombosis complications
- Abstract
A right-to-left shunt in the presence of normal pulmonary artery pressure is an unusual cause of hypoxemia in an adult who has a patent foramen ovale. We report a rare case of such a shunt-the result of a right atrial thrombus that formed in a hypercoagulable patient after placement of an indwelling central venous catheter for chemotherapy. In order to ascertain the nature of the right atrial mass and to decrease the risk of systemic embolization, the thrombus was surgically removed with the patient on cardiopulmonary bypass.
- Published
- 2007
194. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.
- Author
-
Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, and Croce CM
- Subjects
- Apoptosis, Azacitidine analogs & derivatives, Azacitidine pharmacology, Breast Neoplasms pathology, Cell Proliferation drug effects, Decitabine, Down-Regulation, Female, Humans, Ovarian Neoplasms pathology, ADP-Ribosylation Factors genetics, Genes, Tumor Suppressor, Ovarian Neoplasms genetics
- Abstract
ARLTS1 is a tumor suppressor gene initially described as a low-penetrance cancer gene: a truncated Trp149Stop (MUT) polymorphism is associated with general familial cancer aggregation and, particularly, high-risk familial breast cancer. DNA hypermethylation has been identified as a mechanism of ARLTS1 expression down-regulation in lung carcinomas and B-cell chronic lymphocytic leukemia. We found that, in the majority of ovarian carcinomas (61.5%) and in a significant proportion of ovarian and breast cancer cell lines (45%), ARLTS1 is strongly down-regulated due to DNA methylation in its promoter region. After ARLTS1 restoration by adenoviral transduction, only the negative TOV-112 and the homozygously mutated (MUT) MCF7 cells, but not the OV-90 cells expressing a normal ARLTS1 product, underwent apoptosis and inhibition of cell growth. Furthermore, ARLTS1 reexpression significantly reduced the tumorigenic potential of TOV-112 in nude mice. On the contrary, the ARLTS1-MUT induced significantly lower levels of apoptosis in infected cells and reduced in vivo tumorigenesis only partially, supporting the hypothesis that Trp149Stop polymorphism is retained in the general population and predisposes to cancer because of a reduction, but not full loss, of normal ARLTS1 function.
- Published
- 2006
- Full Text
- View/download PDF
195. WWOX gene restoration prevents lung cancer growth in vitro and in vivo.
- Author
-
Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, Yendamuri S, Han SY, Amadori D, Huebner K, and Croce CM
- Subjects
- Adenoviridae genetics, Animals, Apoptosis, Cell Cycle, Cell Line, Tumor, Female, Humans, Lung Neoplasms pathology, Mice, Tumor Suppressor Proteins, WW Domain-Containing Oxidoreductase, Lung Neoplasms prevention & control, Oxidoreductases genetics
- Abstract
The WWOX (WW domain containing oxidoreductase) gene at the common fragile site, FRA16D, is altered in many types of cancer, including lung cancer. We have examined the tumor suppressor function of WWOX in preclinical lung cancer models. The WWOX gene was expressed in lung cancer cell lines through recombinant adenovirus (Ad) infection (Ad-WWOX), and through a drug [ponasterone A, (ponA)]-inducible system. After WWOX restoration in vitro, endogenous Wwox protein-negative cell lines (A549, H460, and H1299) underwent apoptosis through activation of the intrinsic apoptotic caspase cascade in A549 and H460 cells. Ectopic expression of Wwox caused dramatic suppression of tumorigenicity of A549, H460, and H1299 cells in nude mice after Ad-WWOX infection and after ponA induction of Wwox expression in H1299 lung cancer cells. Tumorigenicity and in vitro growth of U2020 (Wwox-positive) lung cancer cells was unaffected by Wwox overexpression. This study confirms that WWOX is a tumor suppressor gene and is highly effective in preventing growth of lung cancer xenografts, whether introduced through viral infection or by induction of a silent WWOX transgene.
- Published
- 2005
- Full Text
- View/download PDF
196. Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo.
- Author
-
Trapasso F, Yendamuri S, Dumon KR, Iuliano R, Cesari R, Feig B, Seto R, Infante L, Ishii H, Vecchione A, During MJ, Croce CM, and Fusco A
- Subjects
- Animals, Cell Division, Cell Line, Tumor, DNA Primers, Exons genetics, Genotype, Humans, Kinetics, Pancreatic Neoplasms genetics, Polymerase Chain Reaction, Rats, Receptor-Like Protein Tyrosine Phosphatases, Class 3, Reverse Transcriptase Polymerase Chain Reaction, Transfection, Genes, Tumor Suppressor, Pancreatic Neoplasms enzymology, Pancreatic Neoplasms pathology, Protein Tyrosine Phosphatases genetics, Protein Tyrosine Phosphatases metabolism
- Abstract
DEP-1/HPTPeta, a receptor-type protein tyrosine phosphatase, is a candidate tumor suppressor gene because its expression was blocked in rat and human thyroid transformed cells, and its restoration reverted their neoplastic phenotype. In addition, loss of DEP-1/HPTPeta heterozygosity has been described in mammary, lung and colon primary tumors. We now show that DEP-1/HPTPeta is drastically reduced in several cell lines originating from human epithelial pancreatic carcinomas compared with normal pancreatic tissue. We also show that the infection of AsPC1 and PSN1 cells with a recombinant adenovirus carrying r-PTPeta cDNA (the rat homolog of DEP-1/HPTPeta) inhibits their proliferation. Flow cytometric analysis of the infected cells demonstrated that restoration of r-PTPeta activity disrupts their cell cycle and leads to apoptosis. Finally, the growth of PSN1 xenograft tumors was blocked by the intratumoral injection of a recombinant adeno-associated virus carrying r-PTPeta. The data suggest that restoration of DEP-1/HPTPeta expression could be a useful tool for the gene therapy of human pancreatic cancers.
- Published
- 2004
- Full Text
- View/download PDF
197. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models.
- Author
-
Trapasso F, Sarti M, Cesari R, Yendamuri S, Dumon KR, Aqeilan RI, Pentimalli F, Infante L, Alder H, Abe N, Watanabe T, Viglietto G, Croce CM, and Fusco A
- Subjects
- Adenoviridae genetics, Animals, Down-Regulation, Green Fluorescent Proteins metabolism, HMGA1a Protein genetics, HMGA1a Protein metabolism, Humans, Male, Mice, Mice, Nude, Oligonucleotides, Antisense pharmacology, Pancreatic Neoplasms genetics, Transplantation, Heterologous, Tumor Cells, Cultured, Apoptosis, Cell Proliferation drug effects, HMGA1a Protein antagonists & inhibitors, Models, Animal, Pancreatic Neoplasms therapy
- Abstract
Pancreatic carcinoma is one of the most aggressive tumors, and, being refractory to conventional therapies, is an excellent target for new therapeutic approaches. Based on our previous finding of high HMGA1 expression in pancreatic cancer cells compared to normal pancreatic tissue, we evaluated whether suppression of HMGA1 protein expression could be a treatment option for patients affected by pancreatic cancer. Here we report that HMGA1 proteins are overexpressed in pancreatic carcinoma cell lines, and their downregulation through an adenovirus carrying the HMGA1 gene in an antisense orientation (Ad Yas-GFP) results in the death of three human pancreatic carcinoma cell lines (PANC1, Hs766T and PSN1). Pretreatment of PANC1 and PSN1 cells with Ad Yas-GFP suppressed and reduced, respectively, their ability to form xenograft tumors in nude mice. To further verify the role of HMGA1 in pancreatic tumorigenesis, we used a HMGA1 antisense phosphorothioate oligodeoxynucleotide (ODN); its addition induced a decrease in HMGA1 protein levels and a significant reduction of the proliferation rate of PANC1-, Hs766T- and PSN1-treated cells. Therefore, suppression of HMGA1 protein synthesis by an HMGA1 antisense approach seems to be a feasible treatment strategy in pancreatic carcinomas.
- Published
- 2004
- Full Text
- View/download PDF
198. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer.
- Author
-
Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, Fishel R, and Croce CM
- Subjects
- Animals, Carcinoma, Non-Small-Cell Lung metabolism, Cell Cycle, Cell Division, Cell Line, Tumor, DNA Methylation, DNA Mutational Analysis, DNA, Complementary metabolism, Exons, Gene Deletion, Gene Expression Regulation, Neoplastic, Homozygote, Humans, Lentivirus genetics, Loss of Heterozygosity, Lung Neoplasms metabolism, Mice, Mice, Nude, Microsatellite Repeats, Models, Genetic, Mutation, Neoplasm Transplantation, Polymorphism, Genetic, Reverse Transcriptase Polymerase Chain Reaction, Time Factors, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms genetics, Ubiquitin-Protein Ligases biosynthesis, Ubiquitin-Protein Ligases genetics
- Abstract
Purpose: Parkin, a gene mutated in autosomal recessive juvenile Parkinsonism and mapped to the common fragile site FRA6E on human chromosome 6q25-q27, is associated with a frequent loss of heterozygosity and altered expression in breast and ovarian carcinomas. In addition, homozygous deletions of exon 2 creating deleterious truncations of the Parkin transcript were observed in the lung adenocarcinoma cell lines Calu-3 and H-1573, suggesting that the loss of this locus and the resulting changes in its expression are involved in the development of these tumors., Experimental Design: We examined 20 paired normal and non-small cell lung cancer samples for the presence of Parkin alterations in the coding sequence and changes in gene expression. We also restored gene expression in the Parkin-deficient lung carcinoma cell line H460 by use of a recombinant lentivirus containing the wild-type Parkin cDNA., Results: Loss of heterozygosity analysis identified a common region of loss in the Parkin/FRA6E locus with the highest frequency for the intragenic marker D6S1599 (45%), and semi-quantitative reverse transcription-PCR revealed reduced expression in 3 of 9 (33%) lung tumors. Although we did not observe any in vitro changes in cell proliferation or cell cycle, ectopic Parkin expression had the ability to reduce in vivo tumorigenicity in nude mice., Conclusion: These data suggest that Parkin is a tumor suppressor gene whose inactivation may play an important role in non-small cell lung cancer tumorigenesis.
- Published
- 2004
- Full Text
- View/download PDF
199. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis.
- Author
-
Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, Rattan S, Cesari R, Nolli ML, Williams NN, Mori M, Kanematsu T, and Croce CM
- Subjects
- Adenocarcinoma metabolism, Alleles, Antimetabolites, Antineoplastic pharmacology, Apoptosis, Azacitidine pharmacology, Blotting, Western, Cell Cycle, Cell Line, Tumor, Cell Separation, Cell Transformation, Neoplastic, DNA Methylation, DNA Mutational Analysis, DNA, Complementary metabolism, Decitabine, Exons, Flow Cytometry, Humans, Loss of Heterozygosity, Oxidoreductases genetics, Pancreatic Neoplasms metabolism, Promoter Regions, Genetic, Protein Structure, Tertiary, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transfection, Tumor Suppressor Proteins, WW Domain-Containing Oxidoreductase, Azacitidine analogs & derivatives, Genes, Tumor Suppressor, Oxidoreductases physiology, Pancreatic Neoplasms genetics
- Abstract
Purpose: WWOX (WW domain containing oxidoreductase) is a tumor suppressor gene that maps to the common fragile site FRA16D. We showed previously that WWOX is frequently altered in human lung and esophageal cancers. The purpose of this study was to delineate more precisely the role of WWOX in pancreatic carcinogenesis., Experimental Design: We analyzed 15 paired pancreatic adenocarcinoma samples and 9 pancreatic cancer cell lines for WWOX alterations. Colony assay and cell cycle analysis were also performed to evaluate the role of the WWOX as a tumor suppressor gene., Results: Loss of heterozygosity at the WWOX locus was observed in 4 primary tumors (27%). Methylation analysis showed that site-specific promoter hypermethylation was detected in 2 cell lines (22%) and treatment with the demethylating agent 5-aza-2'-deoxycytidine demonstrated an increase in the expression of WWOX. In addition, 2 primary tumor samples (13%) showed promoter hypermethylation including the position of site-specific methylation. Transcripts missing WWOX exons were detected in 4 cell lines (44%) and in 2 tumor samples (13%). Real-time reverse transcription PCR revealed a significant reduction of WWOX expression in all of the cell lines and in 6 primary tumors (40%). Western blot analysis showed a significant reduction of the WWOX protein in all of the cell lines. Furthermore, transfection with WWOX inhibited colony formation of pancreatic cancer cell lines by triggering apoptosis., Conclusion: These results indicate that the WWOX gene may play an important role in pancreatic tumor development.
- Published
- 2004
- Full Text
- View/download PDF
200. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.
- Author
-
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, and Croce CM
- Subjects
- Chromosome Mapping, Cloning, Molecular, Databases, Nucleic Acid, Genes, Homeobox, Genetic Markers, Humans, Loss of Heterozygosity, Multigene Family, PubMed, Chromosome Fragile Sites genetics, Genome, Human, MicroRNAs genetics, Neoplasms genetics
- Abstract
A large number of tiny noncoding RNAs have been cloned and named microRNAs (miRs). Recently, we have reported that miR-15a and miR-16a, located at 13q14, are frequently deleted and/or down-regulated in patients with B cell chronic lymphocytic leukemia, a disorder characterized by increased survival. To further investigate the possible involvement of miRs in human cancers on a genome-wide basis, we have mapped 186 miRs and compared their location to the location of previous reported nonrandom genetic alterations. Here, we show that miR genes are frequently located at fragile sites, as well as in minimal regions of loss of heterozygosity, minimal regions of amplification (minimal amplicons), or common breakpoint regions. Overall, 98 of 186 (52.5%) of miR genes are in cancer-associated genomic regions or in fragile sites. Moreover, by Northern blotting, we have shown that several miRs located in deleted regions have low levels of expression in cancer samples. These data provide a catalog of miR genes that may have roles in cancer and argue that the full complement of miRs in a genome may be extensively involved in cancers.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.